Known targets — ChEMBL curated mechanism
rplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Meclocycline. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 14/20 | 0.59 |
| ▸ | KDM4E | B2RXH2 | 11/20 | 0.59 |
| ▸ | MEN1 | O00255 | 9/20 | 0.59 |
| ▸ | KMT2A | Q03164 | 9/20 | 0.59 |
| ▸ | USP2 | O75604 | 8/20 | 0.59 |
| ▸ | HSD17B10 | Q99714 | 8/20 | 0.59 |
| ▸ | RECQL | P46063 | 7/20 | 0.59 |
| ▸ | HPGD | P15428 | 7/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.59 |
| ▸ | THRB | P10828 | 6/20 | 0.59 |
| ▸ | MAPT | P10636 | 6/20 | 0.59 |
| ▸ | LMNA | P02545 | 4/20 | 0.59 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.59 |
| ▸ | CASP7 | P55210 | 2/20 | 0.59 |
| ▸ | CASP1 | P29466 | 1/20 | 0.59 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.59 |
| ▸ | NR1I2 | O75469 | 3/20 | 0.54 |
| ▸ | MC4R | P32245 | 1/20 | 0.54 |
| ▸ | SIRT5 | Q9NXA8 | 1/20 | 0.54 |
| ▸ | POLB | P06746 | 4/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Meclocycline SCHEMBL24321867 | 1.00 | TDP1 (0.59) | TDP1KDM4EMEN1KMT2AUSP2 | |
| Meclocycline SCHEMBL21133273 | 1.00 | TDP1 (0.59) | TDP1KDM4EMEN1KMT2AUSP2 | |
| Meclocycline SCHEMBL29427550 | 1.00 | TDP1 (0.59) | TDP1KDM4EMEN1KMT2AUSP2 | |
| Meclocycline SCHEMBL21133274 | 1.00 | TDP1 (0.59) | TDP1KDM4EMEN1KMT2AUSP2 | |
| Meclocycline SCHEMBL3445 | 1.00 | TDP1 (0.59) | TDP1KDM4EMEN1KMT2AUSP2 | |
| Meclocycline SCHEMBL5505495 | 0.99 | TDP1 (0.58) | TDP1KDM4EMEN1KMT2AUSP2 | |
| Meclocycline SCHEMBL4207351 | 0.99 | TDP1 (0.58) | TDP1KDM4EMEN1KMT2AUSP2 | |
| Meclocycline SCHEMBL4207355 | 0.99 | TDP1 (0.58) | TDP1KDM4EMEN1KMT2AUSP2 | |
| Meclocycline SCHEMBL5505493 | 0.99 | TDP1 (0.58) | TDP1KDM4EMEN1KMT2AUSP2 | |
| Meclocycline SCHEMBL2072677 | 0.94 | TDP1 (0.61) | TDP1KDM4EMEN1KMT2AUSP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1342 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260108455-A1 | DEVICE FOR SUSTAINED CONTROLLED RELEASE OF A THERAPEUTICALLY ACTIVE SUBSTANCE AND USES THEREOF | HYLOMORPH AG (CH) | 2026-04-23 | — | — | US | claimed |
| EP-4554557-B1 | DEVICE FOR SUSTAINED CONTROLLED RELEASE OF A THERAPEUTICALLY ACTIVE SUBSTANCE AND USES THEREOF | HYLOMORPH AG (CH) | 2026-03-11 | — | — | EP | claimed |
| EP-4554557-A1 | DEVICE FOR SUSTAINED CONTROLLED RELEASE OF A THERAPEUTICALLY ACTIVE SUBSTANCE AND USES THEREOF | Hylomorph AG (CH) | 2025-05-21 | — | — | EP | claimed |
| US-20250099557-A1 | ANTIBIOTIC PHARMACEUTICAL COMPOSITION CAPABLE OF SUBCUTANEOUS ADMINISTRATION | SHANGHAI BAO PHARMACEUTICALS CO., LTD. (CN) | 2025-03-27 | — | — | US | claimed |
| US-20240350814-A1 | METHOD FOR PREPARING AN IMPLANTABLE DEVICE | HYLOMORPH AG (CH) | 2024-10-24 | — | — | US | claimed |
| EP-4374848-A1 | ANTIBIOTIC PHARMACEUTICAL COMPOSITION CAPABLE OF SUBCUTANEOUS ADMINISTRATION | Shanghai Bao Pharmaceuticals Co., Ltd. (CN) | 2024-05-29 | — | — | EP | claimed |
| EP-4362998-A1 | METHOD FOR PREPARING AN IMPLANTABLE DEVICE | Hylomorph AG (CH) | 2024-05-08 | — | — | EP | claimed |
| WO-2024012883-A1 | DEVICE FOR SUSTAINED CONTROLLED RELEASE OF A THERAPEUTICALLY ACTIVE SUBSTANCE AND USES THEREOF | HYLOMORPH AG (CH) | 2024-01-18 | — | — | WO | claimed |
| US-11725227-B2 | Devices and methods for examining drug effects on microorganisms | ESSENLIX CORPORATION (US) | 2023-08-15 | — | — | US | claimed |
| US-20230149428-A1 | METHOD OF TREATING GENE THERAPY ASSOCIATED TOXICITY WITH ANTIBIOTICS | ASKLEPIOS BIOPHARMACEUTICAL, INC. (US) | 2023-05-18 | — | — | US | claimed |
| US-20040131628-A1 | Nucleic acids for the treatment of disorders associated with microorganisms | BRATZLER ROBERT L (US) | 2004-07-08 | — | — | US | claimed |
| US-20030105066-A1 | Nitrate salts of antimicrobial agents | NICOX S.A. (FR) | 2003-06-05 | — | — | US | claimed |
| EP-1253924-A1 | NITRATE SALTS OF ANTIMICROBIAL AGENTS | NICOX S.A. (FR) | 2002-11-06 | — | — | EP | claimed |
| EP-1139981-A4 | COMPOSITIONS AND METHODS OF USING THE SAME | FOUR STAR PARTNERS (US) | 2002-04-17 | — | — | EP | claimed |
| EP-1139981-A2 | COMPOSITIONS AND METHODS OF USING THE SAME | Four Star Partners (US) | 2001-10-10 | — | — | EP | claimed |
| WO-2001054691-A1 | NITRATE SALTS OF ANTIMICROBIAL AGENTS | NICOX, S.A. (FR) | 2001-08-02 | — | — | WO | claimed |
| US-6245735-B1 | CONJUGATE OF ANTIBIOTIC AND POLYPEPTIDE OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR OR LIPOPOLYSACCHARIDE BINDING FRAGMENT | THE BRIGHAM AND WOMEN'S HOSPITAL, INC. | 2001-06-12 | — | — | US | claimed |
| EP-1073470-A1 | PHARMACEUTICAL COMPOSITIONS CONTAINING COMPOUNDS WITH ACTIVITY FOR THE ENHANCEMENT OF ABSORPTION OF ACTIVE INGREDIENTS | INPHARMA S.A. (CH) | 2001-02-07 | — | — | EP | claimed |
| WO-2000048636-A1 | PHARMACEUTICAL COMPOSITIONS CONTAINING COMPOUNDS WITH ACTIVITY FOR THE ENHANCEMENT OF ABSORPTION OF ACTIVE INGREDIENTS | INPHARMA S.A. (CH) | 2000-08-24 | — | — | WO | claimed |
| WO-2000038617-A2 | COMPOSITIONS AND METHODS OF USING THE SAME | FOUR STAR PARTNERS (US) | 2000-07-06 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260108455-A1 | DEVICE FOR SUSTAINED CONTROLLED RELEASE OF A THERAPEUTICALLY ACTIVE SUBSTANCE AND USES THEREOF | PGF, VEGFA, LDHB | TDP1 4214/4885KDM4E 3915/4885MEN1 1544/4885 |
| US-20030105066-A1 | Nitrate salts of antimicrobial agents | NOS1, NOS3, NOS2 | TDP1 2368/4885KDM4E 4352/4885MEN1 2695/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.